The Sleep Apnea Devices industry is set to grow from US$ 6.47 Billion in 2024 to an impressive US$ 12.23 Billion by 2033, at ...

The global Continuous Positive Airway Pressure (CPAP) market is positioned for notable growth over the forecast period from ...

Early treatment of obstructive sleep apnea may decrease the risk of Parkinson's disease, a new study published Monday finds.

Air Voel, one of Canada’s leading providers of CPAP machines, masks, and sleep-health solutions, today announced the launch of its Sleep Better 2026 Initiative, a nationwide program designed to raise ...

Let's see why these shares could be great long term picks for Aussie investors. The post 2 screaming buy ASX shares I'd hold ...

Discover why ResMed is a top buy with strong fundamentals, robust cash flow, and dividend potential—ideal for recession-proof ...

GLP-1 drugs pose an existential threat to CPAP-makers. ResMed is currently experiencing temporary tailwinds before potential long-term headwinds. ResMed (NYSE: RMD) finds itself in an investment limbo ...

ResMed (NYSE: RMD) finds itself in an investment limbo as revolutionary weight loss drugs create both immediate opportunities and long-term existential questions for the sleep apnea device maker. The ...

(MENAFN- GetNews) Air Voel, a trusted name in sleep and respiratory wellness across Canada, proudly announces the expansion of its product lineup with the latest ResMed BiPAP and CPAP machines, ...

KeyBanc Capital Markets maintained its Overweight rating and $274.00 price target on ResMed (NYSE:RMD) stock following industry observations. The target aligns with broader analyst expectations, with ...